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ABBREVIATIONS 
RHD- rheumatic heart disease 
CCF-congestive cardiac failure 
MI- myocardial infarction 
CHF-congestive heart failure 
SLE- systemic lupus erythematosis 
LVH-left ventricular hypertrophy 
LVF- left ventricular failure 
IHD- ishemic heart disease 
HTN-hypertension 
PND-paroxysmal nocturnal dyspnea 
BUN-blood urea nitrogen 
BNP-brain natriuretic peptide 
CHD- congenital heart disease 
CAHD-coronary artery heart disease 
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PFT-pulmonary function tests 
FVC - Forced Vital Capacity 
FEV1 - Forced Expiratory Volume in One Second 
FEV3 - Forced Expiratory Volume in Three Seconds 
PEFR - Peak Expiratory Flow Rate 
FEF - Forced Expiratory Flow 
MVV - Maximal Voluntary Ventilation 
VC- vital capacity  
RC- residual capacity 
TLC-Total lung capacity 
COPD-chronic obstructive pulmonary disease 
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       INTRODUCTION 
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                         Coronary artery heart disease and rheumatic heart disease are 
among the most  common causes of morbidity and mortality in India. These two 
diseases are the  most  common causes of cardiac failure. Patients with these 
diseases should  have  regular follow-up with doctors. 
 
                    Heart failure is seen to be a highly common disease affecting about 
1% of people in their 50s and increasing rapidly to 10% prevalence in their 
80s.The annual incidence range  is from 0.2%  in 45 to 55 years  of  age to 
4% in  85 to 95 years of age, with approximate doubling in each decade of 
life. Male predominance  is seen because of high incidence of coronary 
artery heart disease  occurring in  males which in turn leads  to 4 times 
increased risk of heart failure. 
 
                      Impaired pulmonary function is common in cardiac patients. 
Respiratory  muscle wasting has been well documented in Rheumatic Heart 
Disease patients. But  Pulmonary Function Test is the least common test that 
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is undergone by the patients. This current study is aimed to assess the 
Pulmonary Function of  cardiac patients with coronary artery heart disease 
and rheumatic heart disease who have recovered from cardiac failure. 
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AIM AND OBJECTIVES 
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 To study the Pulmonary Function Test patterns in patients with coronary  
artery heart disease and Rheumatic Heart Disease who have revived from 
Cardiac Failure. 
 To diagnose any underlying  undiagnosed respiratory problem coexisting 
with cardiac failure. 
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REVIEW OF LITERATURE 
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CARDIAC FAILURE  
                   Cardiac failure is nowadays one of the common cause for 
IMCU admissions in any hospital. It is defined as the inability of the heart to 
pump sufficiently to maintain blood flow to meet the body‟s needs. There 
are numerous causes that lead on to cardiac failure such as Hypertension, 
Coronary Artery Heart Disease, Vavular Heart disease, Cardiomyopathy, 
Anemia, etc. 
                             Many disease processes can impair the pumping efficiency 
of heart leading on to congestive heart failure
[7]
 .Heart failure means the 
inability of the heart to adequately meet the needs of organs and tissues for 
oxygen and nutrients. This decrease in cardiac output is not enough to 
circulate the blood returning to the heart from the body and lungs leading to 
fluid leak from capillary blood vessels. This leads to the symptoms like 
breathing difficulty, weakness and swelling. 
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BLOOD CIRCULATION IN THE BODY:- 
                                      The right side of heart pumps blood to lungs for 
oxygenation
[5]
 while left side pumps blood to rest of the body. Deoxygenated 
blood from the body enters the right atrium through superior and inferior 
vena cavae. Then it flows in to the right ventricle through tricuspid valve 
from where it is pumped into the lungs through the pulmonary artery. In the 
lungs it gets oxygenated, returns to the left atrium via 4 pulmonary veins 
.Then it enters left ventricle and distributed to the organs and tissues of the 
body
[2]
 through aorta and its branches. 
 Oxygen enters RBCs, while Carbon-di-oxide an excretory product of 
metabolism is removed in the lungs. The cycle then repeats. 
 Left heart failure results when left ventricle is not able to pump blood to the 
body and fluid gets back logged, leaks in to the lungs causing 
breathlessness.Right heart failure occurs when right ventricle is not able to 
pump blood from the body in to the lungs for oxygenation. Blood and fluid 
gets back logged in the venous system, leading on to fluid leak into tissues 
and organs. 
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 Both sides of the heart may fail at the same time leading on to biventricular 
heart failure.  
                          Many disease entities can damage the pumping capacity of 
the heart  leading on to CCF. 
The most common causes for CCF are
[6] 
Coronary Artery Heart Disease 
Hypertension 
Chronic Alcoholism 
Valvular Heart Disease  
Toxic /Metabolic Diseases 
Myocarditis 
Congenital Heart Disease 
Arrhythmias 
Cardiomyopathy. 
Less common causes are 
      Viral infections of  heart muscle 
          Hypothyroidism and hyperthyroidism 
Drug induced (NSAIDS , steroids, Pioglitazone, CCB) 
            Amyloidosis 
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 Emphysema 
 Severe Anemia 
 Iron overload 
 Sarcoidosis 
Causes of refractory cardiac failure 
 Silent MI 
 Pulmonary emboli 
 Thyrotoxicosis 
 LV aneurysm 
Silent valvular stenosis 
BeriBeri 
Anemia 
Myocarditis 
Infection 
Infective endocarditis 
Cardiac tamponade 
SA / AV nodal dysfunction 
RISK FACTORS OF CHF[4] 
   It often results from atherosclerotic heart disease and hence the risk factors 
are the same. 
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 Uncontrolled hypertension 
 Increased blood cholesterol 
 Diabetes 
 Smoking 
 Family history 
 Obstructive sleep apnoea 
 Alcohol 
 Drug abuse 
 Connective tissue disorders like SLE 
   Many patients will have a stable CHF that can decompensate on bodily 
changes. Suppose a patient with compensated CHF  may be doing well  but when 
something like respiratory infections or angina develops, it may precipitate heart 
failure. A decompensatory state may develop acutely when patient takes excessive 
liquid or salt or  not taking  his routine prescribed drugs. 
 
PATHOPHYSIOLOGY 
    Low cardiac output leads to decreased perfusion and inadequate oxygen 
supply along with assosiated decreased cardiac reserve, pulmonary and systemic 
venous compliance. 
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     Compensatory adaptation:- 
  1.Increase in left ventricular mass (LVH) and volume (dilatation) 
  2. Increased systemic vascular resistance 
          3.Activation of renin – angiotensin – aldosterone and vasopressin (ADH)             
system. 
   PRELOAD 
              Preload is the left ventricular end diastolic pressure and it depends on left 
ventricular compliance and venous return. 
 
AFTERLOAD:- 
       Afterload is the left ventricular systolic wall tension that develops during 
ventricular systole and is determined by aortic valve resistance , peripheral 
vascular resistance and elasticity of major blood vessels. 
 
CLASSIFICATION OF CARDIAC FAILURE 
HIGH OUTPUT AND LOW OUTPUT FAILURE
[2] 
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1.HIGH OUTPUT FAILURE 
  The heart is normal and it fails  to maintain a normal or increased 
output during greatly increased demand situations like anemia, 
hyperthyroidism , Paget‟s disease ,A-V malformation , pregnancy. First, 
features of RVF appear , later LVF features become evident. The only clue 
to the development of LVF in patients with high output states is presence of 
shortened circulatory time. 
 
2.LOW OUTPUT FAILURE 
       The heart fails to generate adequate output or can do so with high filling    
pressures. 
           The causes of low output failure are 
i)Intrinsic heart muscle disease (Cardiomyopathy, IHD, Myocarditis, Chagas 
disease) 
ii)Chronic excessive after load (Aortic stenosis , HTN) 
iii)Chronic excessive preload (Mitral Regurgitation) 
iv)Negative inotropic drugs (Anti arrhythmic agents) 
v)Restricted filling (eg. Constrictive pericarditis or tamponade , restrictive 
cardiomyopathy) 
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vi)Extreme bradycardia  (beta blockers , complete heart block) 
 
RIGHT AND LEFT SIDED HEART FAILURE 
1. RIGHT SIDED HEART FAILURE 
  Right sided heart failure is characterised by peripheral edema, 
abdominal discomfort (congestive hepatomegaly), raised JVP and 
hypotension. Usually there is no evidence of pulmonary edema. 
 
2. LEFT SIDED HEART FAILURE 
  The classical feature of LVF is presence of pulmonary edema. Other 
signs are tachypnoea , tachycardia ,S3 ,pulsus alternans & cardiomegaly. 
3.CONGESTIVE HEART FAILURE 
  Congestive heart failure has both the  features of right and left sided 
heart failure. 
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FORWARD AND BACKWARD HEART FAILURE 
1.FORWARD HEART FAILURE 
                    Inadequate pumping of blood into the arterial system leads to 
poor tissue perfusion. Poor renal perfusion results in excessive sodium 
reabsorption  through activation of Renin –Angiotensin-Aldosterone system. 
2.BACKWARD HEART FAILURE 
                    Due to the failure of one or the other ventricle to fill normally 
and discharge its contents, causing an elevated arterial and venous system 
pressure behind the failing ventricle. 
 
SYSTOLIC AND DIASTOLIC FAILURE 
1.SYSTOLIC FAILURE 
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               Systolic failure occurs when there is inadequate cardiac output and 
usually associated with cardiomegaly. Patients with systolic failure are 
usually treated with ionotropic agents. 
 
2.DIASTOLIC FAILURE 
                       Diastolic failure is associated with increased resistance to 
ventricular inflow and reduced ventricular diastolic capacity. The  patients 
are usually managed with vasodilator therapy. 
 
NYHA (New York Heart Association) FUNCTIONAL  
CLASSIFICATION OF HEART FAILURE 
CLASS                       FUNCTIONAL CAPACITY   
 I                     Patient without limitation of physical activity 
 
 
26 
 
II                           Patient with slight limitation of physical capacity in which                             
ordinary physical activity leads  to fatigue, palpitation,   
dyspnoea or angina. 
III                     Patient with marked limitation of physical capacity in which, 
less than ordinary physical activity leads to symptoms of   
heart failure. 
IV                        Symptoms of heart failure even at rest. 
CLINICAL FEATURES:- 
 Signs and symptoms include 
  Dyspnoea on exertion or  dyspnoea at rest 
  Orthopnoea (while lying flat) 
  Paroxysmal nocturnal dyspnoea (May awaken person from sleep) 
  Acute pulmonary edema 
  Chest pain and palpitation 
  Tachycardia 
  Fatigue and weakness 
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  Nocturia and oliguria 
  Anorexia , weight loss 
  Exophthalmos  or visible pulsation of eye 
  Neck vein distension 
  Weak ,rapid and threading pulse 
  Rales , wheeze 
  S3 gallop +/- ,  pulsus alternans 
  Increased intensity of second  heart sound 
  Hepato jugular reflex 
  Ascites ,hepatomegaly ,  anasarca 
  Cyanosis (central and peripheral)  Pallor 
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DIAGNOSIS:- 
1. RELEVANT HISTORY 
2. PROPER PHYSICAL EXAMINATION 
3. INVESTIGATIONS 
i) ECG 
 ECG helps to assess the heart rate, rhythm and indirectly the  size of  
ventricles and blood flow to heart muscle. 
ii) CHEST X-RAY 
 To look for heart size and presence or absence of fluid in the lungs 
 Prominent upper lobe veins- pulmonary capillary wedge pressure >15mmHg 
 Kerley B lines (engorged peripheral lymphatics seen in lower lobe PCWP 
>20mmHg 
 Fluid in the fissures or interlobar effusion known as „phantom tumour‟ as it 
disappears with treatment of left sided failure. 
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 Increase in bronchovascular markings, Chat‟s wing or inverted moustache 
signs- PCWP >25mmHg 
 Pleural effusion – may be unilateral or bilateral 
 Cardiomegaly 
iii) BLOOD TESTS 
 CBC, electrolytes, glucose, BUN and creatinine (to assess kidney function) 
iv) B TYPE NATRIURETIC PEPTIDE 
 This hormone is produced by right and left ventricular muscle cells and released in 
response to stretch, volume overload and elevated filling pressures. It is very 
specific and sensitive. It identifies or excludes heart failure. It is extremely useful 
in diagnosis, prognosis and monitoring the therapy. Serum levels of BNP is  
increased in heart failure and also in asymptomatic LV dysfunction. BNP level  
     < 100pg/ml excludes cardiac failure. 
 Uric acid, CRP, trop I andT, TNF receptors are other biomarkers of heart failure. 
v) ECHOCARDIOGRAPHY 
 To assess the anatomy and function of the heart. It can assess blood flow of the 
heart, chamber enlargement, contractility and   measures ejection fraction. 
vi) ANGIOGRAPHY 
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4. FRAMINGHAM CRITERIA FOR DIAGNOSIS OF 
CCF 
MAJOR CRITERIA:- 
 PND 
 Neck vein engorgement 
 Crackles-lung field 
 Cardiomegaly 
 Acute pulmonary edema 
 S3 gallop 
 Increase venous pressure (>16cm H2O) 
 Positive hepato jugular reflex 
 
MINOR CRITERIA 
 Extremity edema 
 Nocturnal cough 
 Dyspnoea on exertion 
     Pleural effusion 
 Tachycardia (120 bpm) 
 Decreased vital capacity by 1/3 
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MAJOR/ MINOR CRITERIA 
 5 days treatment causing weight loss > or equal to 4.5 kg 
 
FOR DIAGNOSIS: 1 MAJOR +2 MINOR 
 
TREATMENT OF CARDIAC FAILURE:- 
GENERAL PRINCIPLES OF MANAGEMENT:- 
1. Removal of precipitating causes:- 
 Like anemia, arrhythmia, pregnancy, infection, thyroid disorders,smoking and 
alcohol ,drugs, hypertension, MI, pulmonary embolism ,dietary and medical non 
compliance. 
2. Correction of underlying causes like CHD, RHD. 
3. Control of fluid and sodium retention. 
4. Enhancement of myocardial contractility. 
5. Reduction of pulmonary and systemic venous congestion. 
6. Minimisation of cardiac work load. 
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                          In this study we are dealing with coronary artery heart 
disease and rheumatic heart disease patients who were recovered from 
cardiac failure. Hence we discuss a few points from coronary artery heart 
disease and rheumatic heart disease. 
 
CORONARY ARTERY HEART DISEASE:- 
                  Coronary artery heart disease is one of the important causes 
for cardiac failure. It comprises a group of diseases which vary from stable    
angina, unstable angina,  myocardial infarction to sudden cardiac death. 
                         One third of all deaths globally were due to coronary artery 
heart disease. Nearly 7.6 million deaths annually are attributed to coronary 
artery heart disease. By 2030 researchers project that CAHD alone will be 
the cause of more deaths than infectious diseases in developing and under 
developed countries.  
           Chest pain is the most common symptom of CAHD which is 
compressive in nature felt retrosternally radiating to shoulder, arm, jaw, and 
epigastric region getting aggravated on exertion relieved by taking rest or 
 
 
37 
 
nitrates. Other symptoms include fatigue, breathlessness, syncope and 
palpitation. 
 Risk factors for CAHD are 
  1. Hypertension 
  2. Diabetes mellitus 
  3. Smoking 
  4. Alcohol 
  5. Sedentary life style 
  6. Obesity 
  7. Hyperlipidemia 
  8. Depression 
PATHOPHYSIOLOGY:- 
      Decreased blood flow to the cardiac muscle fibres causes ischemia of 
the myocardial cells. These cardiac cells may die due to lack of oxygen and 
this is called myocardial infarction which leads to heart muscle death , 
myocardial scarring without heart muscle regrowth. Atherosclerosis when 
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develops   within the smooth elastic lining inside the coronary artery leads to 
CAHD.  Due to the same, the inner wall of the artery hardens, stiffens and 
swollen with calcium deposits, fatty deposits, certain inflammatory cells  to 
form the plaque. Rupture of these plaques cause  contact  between 
coagulation factors of blood and thrombogenic tissue factor which is 
expressed by macrophage foam cells. If a thrombus formed due to this 
mechanism is non occlusive, an episode of plaque disruption sometimes 
does not cause symptoms or otherwise causes episodic ischemic features. 
Occlusive thrombi  in the absence of collaterals supplying coronary artery 
causes acute myocardial infarction.  
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DIAGNOSIS:- 
 CAHD can be diagnosed using following investigations 
  1.Electrocardiogram(ECG) 
  2.Echocardiogram 
  3.Cardiac enzymes 
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  4.Stress test 
  5.Cardiac catheterization or Angiogram 
  6.Heart scan 
  7.Magnetic resonance angiogram 
TREATMENT:- 
 Treatment for CAHD include 
  1.PCI 
  2.Antifibrinolytics such as streptokinase and urokinase 
  3. Injection Heparin 
  4.T.Aspirin 
  5.T.Clopidogrel 
  6.T.Atorvastatin 
  7.T.Sorbitrate 
  8.ACE inhibitors like T. Enalapril, T.Ramipril etc. 
  9.Beta blockers like T.Carvedilol , T.Bisoprolol and T.Metaprolol 
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RHEUMATIC HEART DISEASE 
                        RHD which is the most common cause of heart disease in 
children globally,   results in permanent damage to the heart specifically 
heart valves following   rheumatic fever .The most common valves affected 
in RHD are mitral valve and aortic valve .  Despite its declining trend it still 
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causes a heavy burden in the social and economic life in developing 
countries.  
 Acute rheumatic fever is a post infectious sequelae of pharyngitis caused by 
group A beta hemolytic streptococci . Risk factors of rheumatic fever 
includes overcrowding  , poor sanitation and other conditions causing 
multiple exposure to streptococcus bacteria.  
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CLINICAL FEATURES:- 
  Clinical features of rheumatic fever may vary which includes 
  1. Fever 
  2. Migrating painful joints 
  3. Red hot  inflamed joints 
  4. Small painless subcutaneous nodules 
  5. Chest pain 
  6. Painless ragged raised rash 
  7. Uncontrollable semi purposeful abnormal movements 
  8. Unusual behavior such as inappropriate laughter and crying 
DIAGNOSIS 
  Diagnosis of rheumatic fever is based on revised Jones criteria, which 
says  two major or one major and two minor criteria associated with 
evidence of group A streptococcal infection can be diagnosed as rheumatic 
fever. 
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MAJOR CRITERIA 
    1. Pancarditis 
    2. Migrating polyarthritis involving major joints 
    3. rheumatic chorea ( syndenham‟s) 
    4. Erythema marginatum 
    5. Subcutaneous nodules 
MINOR CRITERIA 
                                1. Fever 
     2. Polyarthralgia 
                                         3. Elevated ESR and leucocyte count 
    4. Prolonged PR interval in ECG 
                                    5. elevated CRP 
SUPPORTING EVIDENCE 
    1. Elevated anti streptolysin O titre 
    2. Positive throat culture  
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    3. Rapid antigen test for group A streptococcus 
    4. Recent scarlet fever 
TREATMENT:- 
  The treatment for acute rheumatic fever includes Injection Crystalline 
Penicillin 1.0 million units i.v 4-6
th 
 hourly for 1 week  or tablet Penicillin 
500 mg (250 mg for children) per oral twice daily with tablet Aspirin 80 to 
100 mg/ kg per day for two weeks. The use of glucocorticoids in acute 
rheumatic fever remains controversial. 
PROPHYLAXIS:- 
  Prophylaxis is given by injection Benzathine Penicillin 1.2 million 
units  deep im (6 lakh units if less than 27 kg ) under the following schedule.  
1.Without carditis –5 years following last attack or age 21 whichever is 
longer 
2.With carditis but no residual valvular lesion- 10 years following last 
attack or age 21 whichever is longer. 
3.Persistent valvular lesion-  lifelong . 
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LUNG FUNCTION TESTS   
Lung function tests
[9]
  measure how lungs take in air and exhale and 
also how efficiently they transfer oxygen into the blood. There are a lot of 
tests included in Pulmonary function tests.It is a generic term used to 
indicate a battery of studies or  manoeuvres  that may be performed using 
standardized equipment to measure lung function. 
 It evaluates one or more aspects of the respiratory system 
– Respiratory mechanics 
– Lung parenchymal function/ Gas exchange 
– Cardiopulmonary interaction 
 
 Pulmonary function tests can be classified broadly into 
MECHANICAL/ VENTILATORY FUNCTIONS OF LUNG / CHEST WALL 
 BED SIDE PULMONARY FUNCTION TESTS 
 STATIC LUNG VOLUMES & CAPACITIES – VC, IC, IRV, ERV, 
RV,FRC. 
 DYNAMIC LUNG VOLUMES –FVC, FEV1, FEF 25‐75%, 
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PEFR, MVV, RESP. MUSCLE STRENGTH 
 
GAS‐ EXCHANGE TESTS  
 ALVEOLAR‐ARTERIAL PO2 GRADIENT 
  DIFFUSION CAPACITY 
  GAS DISTRIBUTION TESTS‐ 
1) SINGLE  BREATH N2 TEST.   
2) MULTIPLE  BREATH N2 TEST 
3) HELIUM  DILUTION METHOD          
4) RADIO Xenon SCINITIGRAM 
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SPIROMETRY: CORNERSTONE OF ALL PFTs. 
 John hutchinson – invented spirometer. 
 “Spirometry is a medical test that measures the volume of air an individual 
inhales or exhales as a function of time.” 
 CAN‟T MEASURE – FRC, RV, TLC 
                        The main gadget  used in pulmonary function testing is the 
spirometer. It is designed to measure changes in volume and can only 
measure lung volume in chambers  that exchanges  gas with the atmosphere. 
Spirometers with electronic signal outputs (pneumotachs) also measure flow 
(volume per unit of time). A device is usually always attached to the 
spirometer which measures the movement of gas in and out of the chest and 
is referred to as a spirograph. Sometimes the spirograph is replaced by a 
printer like unit. The  resulting  tracing is called a spirogram. Many 
computerized systems have complex spirographs or printouts that show the 
predicted values next to the observed values (the values actually measured). 
The unit will have in memory all of the prediction tables for males and 
females across all age groups. In special spirometers, there are special tables 
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of normal values programmed into the machine for selection when Blacks, 
children or other groups are being tested who may vary from the normal PFT 
tables established for caucasian adults. 
There are a few variables such as age, gender and body size which may have an 
impact on the lung function of one individual compared to another. 
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INDICATIONS FOR SPIROMETRY
[12] 
1.DETECTING PULMONARY DISEASE 
History of pulmonary symptoms 
      Chest pain or orthopnea 
      Cough or phlegm production 
      Dyspnea or wheezing 
 
Physical findings 
      Chest wall deformities 
      Cyanosis 
      Decreased respiratory sounds 
      Finger clubbing 
Abnormal laboratory findings 
      Abnormal blood gas analysis 
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Abnormal Chest xray 
2.ASSESSING SEVERITY OR PROGRESSION OF DISEASE 
Pulmonary diseases 
     Chronic obstructive pulmonary disease 
     Cystic fibrosis 
     Interstitial lung diseases 
     Sarcoidosis 
 
Cardiac diseases 
    Congestive heart failure 
    Congenital heart disease 
     Pulmonary hypertension 
Neuromuscular diseases 
     Amyotrophic lateral sclerosis 
       Guillain-Barré syndrome 
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     Multiple sclerosis 
      Myasthenia gravis 
3.RISK STRATIFICATION OF PATIENTS FOR SURGERY 
Thoracic surgeries 
    Lobectomy 
    Pneumonectomy 
Cardiac surgeries 
    Coronary bypass 
     Correction of congenital abnormalities 
Valvular surgery 
Organ transplantation 
General surgical procedures 
     Cholecystectomy 
     Gastric bypass 
4. EVALUATING DISABILITY OR IMPAIRMENT 
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      Social Security or other compensation programs 
     Legal or insurance evaluations 
 
CONTRAINDICATIONS OF SPIROMETRY 
Acute disorders affecting test performance (e.g.,vomiting, nausea, vertigo) 
Hemoptysis of unknown origin (FVC maneuver may aggravate underlying 
condition.) 
Pneumothorax 
Recent abdominal or thoracic surgery 
Recent eye surgery (increases in intraocular pressure during spirometry) 
Recent myocardial infarction or unstable angina 
Thoracic aneurysms (risk of rupture because of  increased thoracic pressure) 
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FACTORS AFFECTING SPIROMETRY VALUES
[10] 
Age: 
The natural elasticity of the lungs decreases with age. As age 
increases  lung volumes and capacities become smaller and smaller. So it is 
important to compare the  results of a normal person of the same age and 
gender while interpreting spirometry values. 
Gender: 
 Usually males have more lung volumes and capacities compared to 
females even when they are matched for height and weight. Because of this 
difference in lung volumes and capacities, different normal tables must be 
used for males and females. 
 Body Height &Size: 
 Body size has huge effects on PFT values.The PFT result of a small 
man will be smaller than a man of the same age who is much larger. Normal 
tables give predicted PFT data for males or females of a certain age and 
height by accounting for this variable .As people age they begin to increase 
their body mass by increasing their body fat to lean body mass ratio. The 
abdominal mass prevents the diaphragm from descending as far as it could 
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and the PFT results will be below  the  expected  PFT values - i.e. the 
observed (measured)values are actually smaller than the predicted values 
(predicted values from the normal tables) if they become too obese. 
 
Race: 
 The PFT values are affected by race also. Blacks, Hispanics and 
Native Americans have different PFT results compared to Caucasians. 
Hence while interpreting PFT values of a patient , we should use a race 
appropriate table to compare the patient's measured pulmonary function 
against the results of the normal table written for that patient's racial group.  
The degree of effect on PFT is not clearly understood  for other 
factors such as environmental factors and altitude but may have effect on 
PFT. 
 
 
PREPARING THE PATIENT  
The patientsshould be comfortable and they should be seated since 
there is a chance of faintness or syncope during the procedure. Before doing 
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the test the purpose of the test should be explained to the patient .Ideally the 
correct technique is demonstrated before asking the patient to use a 
spirometer for the first time. And ask the patient to have some practice 
sessions  before the readings are taken. Encourage the patient to keep 
blowing out so that maximal exhalation can be achieved. The total number 
of times the patient takes for  practice and recording  is limited to eight or 
less at each session. 
 
 
SPIROMETRIC VALUES 
Lung function is physiologically divided into four volumes: expiratory 
reserve volume, inspiratory reserve volume, residual volume, and tidal 
volume. The sum of all these four volumes  make the total lung capacity 
(TLC). Lung volumes and their combinations measure various lung 
capacities such as functional residual capacity(FRC), inspiratory capacity, 
and VC.
[11] 
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FVC - Forced Vital Capacity :- 
This is the volume of air which can be forcibly and maximally 
exhaled out of the lungs after a deep inspiration . FVC is usually expressed 
in units called liters. This PFT value is  very significant in the diagnosis of 
obstructive and restrictive diseases. 
 
FEV1 - Forced Expiratory Volume in One Second  
This is the amount of air which can be forcibly exhaled from the lungs 
in the first second of a forced expiratory manoeuvre. It is expressed as litres 
This PFT value is  very significant in the diagnosis of obstructive and 
restrictive diseases. 
FEV1/FVC - FEV1 Percent (FEV1%) 
This measurement  is the ratio of FEV1 to FVC - it indicates what 
percentage of the total FVC was expelled from the lungs during the first 
second of forced exhalation - this number is called FEV1%, %FEV1 or 
FEV1/FVC ratio. This value  helps in the diagnosis of obstructive and 
restrictive diseases. 
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FEV3 - Forced Expiratory Volume in Three Seconds 
This is the volume of air which can be forcibly exhaled in three 
seconds - measured in Litres - this volume usually is almost close to the  
FVC, since in the normal individual  most of the air in the lungs can be 
forcibly exhaled in three seconds. 
FEV3/FVC - FEV3% 
This number is the ratio of FEV3 to the FVC - it indicates what 
percentage of the total FVC was expelled during the first three seconds of 
forced exhalation. This is called %FEV3 or FEV3%. 
PEFR - Peak Expiratory Flow Rate 
 This is maximum flow rate achieved by the patient during the forced 
vital capacity manoeuvre beginning after full inspiration and starting and 
ending with maximal expiration - it can either be measured in L/sec or L/min 
- this is a useful measure to see if the treatment is improving obstructive 
diseases like bronchoconstriction due to asthma. 
FEF - Forced Expiratory Flow  
 Forced expiratory Flow is a measure of how much air can be expired 
from the lungs. It is a flow rate measurement. It is measured as liters/second 
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or liters/minute. The FVC expiratory curve is divided into quartiles and 
therefore there is a FEF that existsfor each quartile. The quartiles are 
expressed as FEF25%, FEF50%, and FEF75% of FVC. 
FEF25% 
This measurement describes the amount of air that was forcibly 
expelled in the first 25% of the total forced vital capacity test. 
FEF50% 
This measurement describes the amount of air expelled from the lungs 
during the first half (50%) of the forced vital capacity test. This test is useful 
when looking for obstructive disease.The amount of air that will have been 
expired in an obstructed patient is smaller than that measured in a normal 
patient. 
FEF25%-75% 
 This measurement describes the amount of air expelled from the 
lungs during the middle half of the forced vital capacity test. Many 
physicians like to look at this value because it is an indicator of obstructive 
disease. 
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MVV - Maximal Voluntary Ventilation: - 
This value is determined by having the patient breathe in and out as 
rapidly and fully as possible for 12 -15 seconds - the total volume of air 
moved during the test. Usually expressed as L/sec or L/min . The value helps 
to assess the status of the respiratory muscles, compliance of the thorax-lung 
complex, and airway resistance. Drawback of the test is that it is effort 
dependant and therefore can be a poor predictor of true pulmonary strength 
and compliance. 
 
MEASURMENT   OF  FEV1  AND FVC 
 
      To measure the values first attach a disposable, clean, one-way 
mouthpiece to the spirometer (a fresh one for each patient) and the patient is 
asked to breathe in as deeply as possible (full inspiration). 
      The patient should hold their breath just long enough to seal their lips. 
The patient should NOT purse their lips as if  blowing a trumpet, and ideally 
should pinch their nose or wear a nose clip. The patient should now blow the 
breath out, forcibly, as hard and as fast as possible, until there is nothing left 
to expel. 
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      Patient should be encouraged  to keep blowing out. Some spirometers 
give a beep to confirm the manoeuvre is complete. Now repeat the procedure 
two times. 
      Ideally three  readings should be obtained of which the best two  
which are within 100ml, or 5%, of each other. Depending on model of 
spirometer the results may be displayed or directly printed into a strip. 
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Spirometry indicates the presence of an abnormality if any of the following 
are recorded: 
• FEV1 <80% predicted normal 
• FVC <80% predicted normal 
• FEV1/FVC ratio <0.7 
Obstructive disorder: 
• FEV1 decreased (<80% predicted normal) 
• FVC is usually found to be reduced but to a smaller extent than  FEV1 
• FEV1/FVC ratio decreased (<0.7) 
Restrictive disorder: 
• FEV1 decreased(<80% predicted normal) 
• FVC decreased (<80% predicted normal) 
• FEV1/FVC ratio normal (>0.7) 
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MEASURING VITAL CAPACITY (VC) 
 
The VC is a non-forced manoeuvre and usually greater than the FVC 
in COPD. It shows more accurate measurement  of lung volume when 
airways are floppy, as in emphysema. It is usually calculated at the 
beginning of the procedure to understand the patient with the equipment. 
• a fresh ,new, clean, disposable, one-way mouthpiece is attatched to the 
spirometer  
•  patient should breathe in as deeply as possible (in full inspiration). 
• Patient is asked to hold their breath just long enough to seal their lips. The 
patient should NOT purse their lips as if blowing a trumpet, and ideally 
should pinch their nose or wear a nose clip. 
• Breathe out steadily, slowly at a comfortable pace. 
• Continue until expiration is complete. 
 
• The measurement of slow VC may allow the assessment of airflow 
obstruction in patients who are unable to perform a forced measurement to 
full exhalation. 
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FLOW-VOLUME MEASUREMENT 
         Spirometers can measure expiratory flow plotted against the volume of air 
exhaled. The graph produced is called a flow-volume curve. The overall shape 
of the flow-volume curve is helpful for detecting airflow obstruction at an early 
stage, and yields additional information to the volume-time curve. However, 
interpretation of the flow-volume curve must take into account the values of 
FEV1 and FVC (as a % of predicted normal). 
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Normal flow-volume curves 
On exhalation, there is a fast rise to the maximal expiratory flow 
continued by a steady, uniform decrease until all the air is exhaled. 
Obstructive disorder: 
        In a patient with obstructive airways disease, the peak expiratory flow 
(PEF) is decreased  and the decline in airflow to complete exhalation follows 
a distinctive dipping (or concave) curve. 
 
Severe obstructive disorder: 
                  In a severe airflow obstruction, especially  with emphysema, the 
characteristic „steeple pattern‟ is seen in the expiratory flow graph. 
Restrictive disorder: 
        The graph observed in the expiratory trace of a patient with restrictive 
defect is normal in shape but there is an absolute reduction in volume. 
  There are many studies done globally in assessing the pulmonary 
function test in cardiac patients .Certain studies indicated impaired 
pulmonary function is common in cardiac patients but more deterioration 
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was found as a complication following coronary artery bye pass graft 
surgery rather than CAHD and RHD . Respiratory muscle weakness was 
documented in various studies in rheumatic valvular heart disease such as 
mitral stenosis . 
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                                MATERIALS AND METHODS 
      This study is a observational study conducted in Department of  
Medicine, Tirunelveli Medical College Hospital. Seventy five patients 
admitted in TVMCH from MAY 2014 to MAY 2015 will participate in the 
study. The volunteer patients who met the inclusion criteria, signed a 
consent form after they got a clear explanation of the spirometry evaluation 
procedures. 
Inclusion Criteria : 
 Adult patients with Rheumatic Heart Disease (Male and Female) 
 Coronary artery heart disease patients less than 60 years of age  (Male and 
Female) 
Exclusion Criteria : 
 Pediatric patients less than 12 years of age and Adult patients more than 60 
years of age 
 Rheumatic Heart disease patients with known respiratory disease (COPD, 
BronchialAsthma, Pulmonary Tuberculosis) 
 CAHD patients with known respiratory disease(COPD, 
BronchialAsthma,Pulmonary Tuberculosis) 
 Morbid and sick patients 
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 Severe Left Ventricular Dysfunction patients as per ECHO report. 
DATA COLLECTION    
 Detailed medical history and physical examination will be done 
 Basic Laboratory investigations such as complete blood count , RFT and 
Urine analysis done 
 ECG  
 X-Ray Chest PA view 
 Echocardiogram 
 Spirometry test 
SPIROMETER 
       The spirometry is performed using a device called a spirometer,which 
comes in several different varieties. Most spirometers display the following 
graphs,calledspirograms: 
 A volume-time curve, showing volume (liters)along the Y-axis and time 
(seconds) along the X-axis 
 A flow-volume loop,which graphically depicts the rate of airflow on the Y-
axis and the total volume inspired or expired on the X-axis 
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PROCEDURE 
        The basic forced volume vital capacity (FVC) test varies slighty 
depending on the equipment used. 
 
       Generally, the patient is asked to take the deepest breath they can, and 
then exhale into the sensors hard as possible, for as long as possible, 
preferably at least 6 seconds. It is sometimes directly followed by a rapid 
inhalation(inspiration),in particular when assessing possible upper airway 
obstruction. Sometimes, the test will be preceded by a period of quiet 
breathing in and out from the sensor (tidal volume) or the rapid breath in 
(forced inspiratory part ) will come before the forced exhalation. 
 
      During the test, soft nose clips may be used to prevent air escaping 
through the nose. Filter mouthpieces may be used to prevent the spread of 
microorganisms. 
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LIMITATIONS OF TEST 
       The manoeuvre is highly dependent on patient cooperation and effort, 
and is normally repeated at least three times to ensure reproducibility.  Since 
results are dependent on patient cooperation, FVC can only be 
underestimated, never overestimated. 
 
        Due to the requirement of  patient cooperation , spirometry can only 
be used on children old enough to comprehend and follow the instructions 
given(6 years old or more),and only on patient who are able to understand 
and follow instructions- thus, this test is not suitable for patients who are 
unconscious ,heavily sedated ,or have limitations that would interfere with 
vigorous respiratory efforts. Other types of lung function tests are available 
for infants and unconscious persons. 
 
Another major limitation is the fact that many intermittent or mild 
asthmatics have normal spirometry between acute exacerbation, limiting 
spirometry‟s usefulness as a diagnostic tool. It is more useful as a 
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monitoring tool. A sudden decrease in FEV1 or other spirometric measure in 
the same patient can signal worsening,even if the raw value is still normal. 
Patients are encouraged to record their personal best measures . 
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OBSERVATIONS AND RESULTS 
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 MALE FEMALE TOTAL 
CAHD 28 18 46 
RHD 21 8 29 
TOTAL 49 26 75 
 
 
      Among the 75 patients under study, 49 were male and 28 were female 
patients. Out of 49 male patients, 28 were having CAHD and 21 were 
suffering from rheumatic heart disease. Among the 26 females, 18 were 
found to have CAHD and 8 were suffering from rheumatic heart disease.  
 
 
76 
 
 
  
STUDY POPULATION 
Normal
Obstructive
Restrictive
 
 
77 
 
 MALE FEMALE TOTAL 
NORMAL 26 13 39 
OBSTRUCTIVE 8 4 12 
RESTRICTIVE 15 9 24 
TOTAL 49 26 75 
 
      Among 49 males in study population 26 were found to have normal 
pulmonary function test parameters, 15 showed restrictive pattern and 8 
showed obstructive pattern. Out of 26 females 13 were found to have normal 
pattern , 9 showed restrictive pattern and 4  were found to have obstructive 
pattern. Among total 75 pateints, 39 patients showed normal pft pattern,24 
showed restrictive pattern in pft and 12 were found to have obstructive 
pattern.  
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      46 patients among the study population were CAHD patients. Among 
them 28 were males and 18 were females. Among 28 males, 18 were having 
normal PFT pattern, 5 showed obstructive pattern and 5 showed restrictive 
pattern. Among 18 females, 10 showed normal pattern ,3 showed obstructive 
pattern and 5 showed restrictive pattern.  
 MALE FEMALE TOTAL 
NORMAL 18 10 28 
OBSTRUCTIVE 5 3 8 
RESTRICTIVE 5 5 10 
TOTAL 28 18 46 
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RHD PATIENTS IN STUDY POPULATION 
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 MALE FEMALE TOTAL 
NORMAL 8 3 11 
OBSTRUCTIVE 2 1 3 
RESTRICTIVE 11 4 15 
TOTAL 21 8 29 
 
 
      Among  the study population 29 patients were having rheumatic heart 
disease. 21 were males and 8 were females. Among the 21 males, 8 showed 
normal PFT pattern,3 showed obstructive pattern and 11 were found to have 
restrictive pattern. Among the females , 3 were found to have  normal 
pattern, obstructive pattern in 1 patient and restrictive pattern  seen in 4 
patients .  
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 MALE FEMALE TOTAL 
NORMAL 17 11 28 
OBSTRUCTIVE 4 1 5 
RESTRICTIVE 8 5 13 
TOTAL 29 17 46 
 
 
       Among the study population, 46 were found to be hypertensive. 
Among them, 29 were males and 17 were females. Among 29 males, 17 
were found to have normal PFT pattern, 4 were having obstructive pattern 
and 8 were having restrictive pattern. Out of 17 females 11 were having 
normal PFT pattern, 5 were having obstructive pattern and 13 showed  
restrictive pattern.
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 MALE FEMALE TOTAL 
NORMAL  5 4 9 
OBSTRUCTIVE 2 2 4 
RESTRICTIVE 3 4 7 
TOTAL 10 10 20 
 
       Among the study population , 20 were diagnosed to have 
cardiomegaly on chest radiography. Among the 10 males, 5 were having 
normal PFT values, 2 showed obstructive pattern and 3 showed restrictive 
pattern.among females, 9 were found to have normal PFT study, 4 patients 
were having obstructive pattern and 7 showed restrictive pattern. 
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 STUDY PATIENTS WITH EF > 50% 
NORMAL
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 MALE FEMALE TOTAL 
NORMAL 16 6 22 
OBSTRUCTIVE 1 1 2 
RESTRICTIVE 9 6 15 
TOTAL 26 13 39 
 
      Among the study sample, 39 patients were having ejection fraction 
more than 50%. Among them 26 were male patients and 13 were female 
patients. Among the 26 males, 16 showed normal PFT payyerns,1 showed 
obstructive pattern and 9 were showing restrictive pattern. Among 
females,normal pattern was seen in 6 patients, obstructive pattern in 1 and 
restrictive pattern in 6 patients.  
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STUDY POPULATION WITH EF < 50% 
NORMAL
OBSTRUCTIVE
RESTRICTIVE
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 MALE FEMALE TOTAL 
NORMAL 10 7 17 
OBSTRUCTIVE 6 3 9 
RESTRICTIVE 7 3 10 
TOTAL 23 13 36 
 
 
       Among  the study population 36 patients  were having ejection 
fraction less than50%. Out of these 36 patients,23 were males and 13 were 
females. Among the 23 males 10 were having normal PFT patterns, 6 
showed obstructive pattern and 7 showed restrictive pattern. Out of 13 
females, 7 were having normal PFT pattern, obstructive pattern seen  in3 
patients and restrictive pattern in 3 patients. 
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DISCUSSION 
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                Heart failure is one of the common causes of mortality and morbidity 
of Indian population. However the pulmonary function of such patients has 
not been studied adequately. This study, “STUDY OF PULMONARY 
FUNCTION TESTS IN CARDIAC PATIENTS “is a observational study 
done on 75 patients with cardiac failure admitted in Tirunelveli medical 
college hospital, after they were revived from cardiac failure. 
       A study population included 49 male patients and 26 female patients. 
Of the male patients 29 were diagnosed to be having coronary artery heart 
disease and 20 patients were diagnosed to be having Rheumatic Heart 
Disease. Among the 26 female patients 17 were found to be having coronary 
artery heart disease and 9 were found to be having Rheumatic Heart Disease. 
       In this study pulmonary function test was done on these patients once 
they revived from cardiac failure. The parameters studied were forced 
expiratory volume in first second (FEV1), forced vital capacity (FVC), and 
ratio of FEV1/FVC. From these parameters whether these patients were 
having obstructive or restrictive pattern of respiratory involvement was 
studied. Supportive investigations such as chest x-ray PA view, ECG and 
Echocardiogram was done. 
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       Among the studied patients 52% had normal pattern of pulmonary 
function test, 32% had restrictive pattern and 16% had obstructive pattern. 
Out of the male patients 53.06% had normal pattern, 30.61% had restrictive 
pattern and 16.32% had obstructive pattern. Out of the female patients 
studied, 50% had normal pattern, 34.61% had restrictive pattern and 15.38% 
had obstructive pattern. This shows that both males and females in the study 
population had similar type of distribution of the pulmonary function test 
pattern. 
       61.33% (46) of the studied population had coronary artery disease as 
the cause of heart failure. In them 60.86% of patients had normal pattern of 
PFT, 17.39% had obstructive pattern and 21.73% had restrictive pattern. 
38.66% (29) of the studied patients had rheumatic heart disease as the cause 
of heart failure. Among them 37.93% had normal pulmonary function test 
pattern, while 10.34% had obstructive pattern and 51.72% had restrictive 
pattern. From this it is clear that compared to cardiac failure patients with 
coronary artery disease, patients with rheumatic heart disease had lower 
proportion of patients with normal pulmonary function test pattern. The 
prevalence of restrictive pattern of pulmonary function test was more in 
those with rheumatic heart disease (51.72%) than those with coronary artery 
disease (38.66%). 
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      Among the study population 46 patients (61.33) were found to be 
hypertensive. In them, 60.86% had normal pattern of pulmonary function 
test. 10.86% had obstructive pattern while 28.26% had restrictive pattern. 
       Out of the studied patients 20 (26.66%) had cardiomegaly on chest 
xray. Among them 45% had normal pattern of PFT while 20% had 
obstructive pattern and 35% had restrictive pattern. 
      39 patients (52%) had ejection fraction of more than 50%,. Among 
them, 56.41% had normal pulmonary function tests. 5.12% had obstructive 
pattern and 38.46% had restrictive pattern. 36 patients (48%) had ejection 
fraction less than 50%. Among them, 47.22% had normal pattern of 
pulmonary function test while 25% had obstructive pattern and 27.77% had 
restrictive pattern. The prevalence of obstructive pattern was more in 
patients with left ventricular ejection fraction of less than 50%. 
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CONCLUSION 
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The presence of impaired pulmonary function tests in cardiac failure 
patients has been already demonstrated in various studies. This may be due 
to various reasons like pulmonary congestion, pulmonary hypertension, 
respiratory muscle wasting due to cardiac cachexia and co-existent 
respiratory diseases in patients with cardiac failure. More than half of the 
cardiac failure patients had normal pulmonary function pattern. In those who 
had abnormal pulmonary function pattern, the incidence of restrictive pattern 
was more than that of obstructive pattern. The prevalence of restrictive 
pattern of pulmonary function test was more in patients with rheumatic heart 
disease when compared to patients with coronary artery disease patients for 
unknown reason. As the LV ejection fraction of the patients with cardiac 
failure decreased there is a higher incidence of obstructive pattern of 
pulmonary function test. 
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ANNEXURE 1 
COMMON RESPIRATORY DISEASES BY DIAGNOSTIC METHODS  
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